<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BL-8**  
External request:  
Submission from Foundation Medicine, Inc. company to clarify the footnote “Consider molecular testing in a CLIA-laboratory. See Discussion” (BL-9, Footnote aa) and expand the discussion to indicate that molecular testing is optimally completed as part of a validated comprehensive genomic profiling (CGP) assay1, such as FoundationOne CDx, via a single assay (as opposed to sequential testing of single biomarkers or use of limited molecular diagnostic panels) in order to conserve tissue and to obtain as much information as possible to inform the use of currently available biomarker driven therapies and define/refine clinical trial options. | Based on a review of data and discussion, the panel consensus did not support the addition of these specific recommendations into the Guidelines due to insufficient available data. | 0 13 0 15 |
| **BL-G**  
External request:  
Submission from Bristol-Myers Squibb Company to include as a footnote the following: “Nivolumab FDA approved dose is 240mg IV every 2 weeks or 480mg IV every 4 weeks administered over 30 minutes until disease progression or unacceptable toxicity.” | The panel consensus was this request was outside of the scope of the Guidelines recommendations. | 0 13 0 15 |